December 15, 2020
3 min watch
Save
VIDEO: What breast cancer oncologists can learn from IPATunity130
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Megan Kruse, MD, a medical oncologist at Cleveland Clinic, spoke with Healio about findings from the IPATunity130 trial.
The data presented at this year’s virtual San Antonio Breast Cancer Symposium demonstrated “no significant difference in progression free survival for the combination, experimental arm” compared with the placebo arm.
“Although the phase 2 data were encouraging, the phase 3 data doesn’t seem to hold the same benefit,” Kruse said.
However, she suggested that further analysis of the biomarker data may “hold promise.”
Published by:
Sources/Disclosures
Collapse
Source:
Dent R. Abstract GS3-04. Presented at: San Antonio Breast Cancer Symposium (Virtual); Dec. 8-11, 2020.
Disclosures:
Kruse reports serving on advisory boards for Eisai, Immunomedics, Lilly Oncology, Puma Biotechnology and Seattle Genetics; as a research advisor for Lilly Oncology and as a consultant for Eisai.
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.